Breaking News Instant updates and real-time market news.

AXTA

Axalta Coating

$31.66

-5.89 (-15.69%)

07:45
12/01/17
12/01
07:45
12/01/17
07:45

Axalta Coating fundamentals remain intact, says Baird

Baird analyst Ghansham Panjabi noted Axalta reported its talks with Nippon have ended due to a big divide between them over a takeout price for the company. Although disappointed the negotiations broke down, he said the company has shown a commitment toward building critical mass in a shareholder friendly manner. The analyst said Axalta's fundamentals remain intact and the company is set up for a solid 2018 setup. Panjabi reiterated his Outperform rating and $35 price target on Axalta shares.

AXTA Axalta Coating
$31.66

-5.89 (-15.69%)

11/28/17
KEYB
11/28/17
NO CHANGE
Target $40
KEYB
Overweight
Axalta Coating price target raised to $40 from $36 at KeyBanc
KeyBanc analyst Michael Sison raised his price target for Axalta Coating to $40 from $36 to reflect takeout potential given recent confirmation from Nippon that it has made a proposal to acquire the company. The analyst reiterates an Overweight rating on the shares.
11/30/17
JEFF
11/30/17
NO CHANGE
Target $36
JEFF
Buy
Investors to refocus on Axalta fundamentals after deal talks end, says Jefferies
Jefferies analyst Laurence Alexander said some M&A premium may linger for Axalta Coating but he expects investors to assign a fading M&A view after two deal discussions failed so close together. With merger talks with Nippon Paint ended, he expects investors to shift their focus back to the company's fundamentals, noting also that economic data has improved and the company's pricing initiatives have had time to gain traction since its initial talks with AkzoNobel came to light. Alexander lowered his price target on Axalta to $36 from $38 and keeps a Buy rating on the stock.
11/30/17
SBSH
11/30/17
NO CHANGE
Target $34
SBSH
Neutral
Axalta takeout premium not fully removed, says Citi
Citi analyst P.J. Juvekar says that around $31, Axalta Coating Systems shares have not fully removed a takeout premium. The analyst notes that $28 per share is his bear case scenario if a buyout does not happen. Axalta, remains a leading takeout candidate, but the quick failure of two public negotiations is surprising, Juvekar tells investors in an intraday research note. He still thinks Axalta is a willing seller at the right price, but cautions that the likelihood of a quick deal "seems diminished" following the failure of the Nippon talks. Juvekar has a Neutral rating on Axalta with a $34 price target.
12/01/17
DBAB
12/01/17
NO CHANGE
Target $35
DBAB
Buy
Axalta target raised to $35 after failed deals at Deutsche Bank
The failure of Axalta Coating (AXTA) to reach a takeover deal with either Nippon or AkzoNobel (AKZOY) more reflects the situations at the latter two companies than any concerns or issues with the Axalta's coating businesses, Deutsche Bank analyst David Begleiter tells investors in a research note partially titled "Unwanted but Not Unloved." The analyst raised his price target for Axalta shares to $35 from $32, which reflects 11% upside from current levels. He keeps a Buy rating on the name

TODAY'S FREE FLY STORIES

GME

GameStop

$18.97

-0.23 (-1.20%)

10:10
12/11/17
12/11
10:10
12/11/17
10:10
Options
In the money put buyers in GameStop »

In the money put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KURA

Kura Oncology

$14.90

0.75 (5.30%)

10:07
12/11/17
12/11
10:07
12/11/17
10:07
Hot Stocks
Kura Oncology findings supoort tipifarnib development in bone marrow cancers »

Kura Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIVV

Bioverativ

$51.47

0.76 (1.50%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Hot Stocks
Bioverativ data shows extended dosing with Alprolix provides HepB protection »

Bioverativ and Swedish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XENT

Intersect ENT

$28.60

-1.325 (-4.43%)

10:05
12/11/17
12/11
10:05
12/11/17
10:05
Recommendations
Intersect ENT analyst commentary  »

Intersect ENT approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

CTL

CenturyLink

$15.62

0.9451 (6.44%)

10:04
12/11/17
12/11
10:04
12/11/17
10:04
Technical Analysis
Technical View: CenturyLink higher on Commonwealth of Pennsylvania contract »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMRN

BioMarin

$81.99

1.09 (1.35%)

10:03
12/11/17
12/11
10:03
12/11/17
10:03
Hot Stocks
BioMarin highlights new results for valoctocogene roxaparvovec at ASH »

BioMarin Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

  • 28

    Feb

ABBV

AbbVie

$96.13

0.18 (0.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
AbbVie: Ibrutinib inhibited pre-germinal center B cells in trial »

AbbVie announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$114.46

7.68 (7.19%)

10:02
12/11/17
12/11
10:02
12/11/17
10:02
Hot Stocks
Alexion reports results from Phase 1b/2 studies of ALXN1210 »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

10:01
12/11/17
12/11
10:01
12/11/17
10:01
General news
JOLTS Job Openings data reported »

October JOLTS Job…

CELG

Celgene

$106.09

3.36 (3.27%)

10:00
12/11/17
12/11
10:00
12/11/17
10:00
Options
Sizable put spread in Celgene as shares see strength »

Sizable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Mar

MARK

Remark Holdings

$8.84

1.43 (19.30%)

09:59
12/11/17
12/11
09:59
12/11/17
09:59
Conference/Events
Remark Holdings management to meet with Roth Capital »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CTL

CenturyLink

$15.47

0.795 (5.42%)

, FTR

Frontier Communications

$9.75

0.6 (6.56%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Options
Early notable gainers among liquid option names on December 11th »

Notable gainers among…

CTL

CenturyLink

$15.47

0.795 (5.42%)

FTR

Frontier Communications

$9.75

0.6 (6.56%)

SWN

Southwestern Energy

$5.72

0.225 (4.10%)

MNK

Mallinckrodt

$22.64

0.34 (1.52%)

WYNN

Wynn Resorts

$159.54

0.62 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 14

    Dec

ECR

Eclipse Resources

$2.36

0.21 (9.77%)

09:55
12/11/17
12/11
09:55
12/11/17
09:55
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

XLE

Energy Select Sector SPDR

$69.57

0.29 (0.42%)

09:54
12/11/17
12/11
09:54
12/11/17
09:54
Technical Analysis
Technical View: Energy Select Sector SPDR leads on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$61.50

0.195 (0.32%)

09:51
12/11/17
12/11
09:51
12/11/17
09:51
Upgrade
Nike rating change  »

Follow-up: Nike upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

IBB

iShares Nasdaq Biotechnology Index

$106.07

2.02 (1.94%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Technical Analysis
Technical View: iShares Nasdaq Biotechnology Index breaks out »

The iShares Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.46

0.13 (2.44%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Options
Interest in AK Steel Mar 7 calls continues »

Interest in AK Steel Mar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$73.38

2.82 (4.00%)

09:48
12/11/17
12/11
09:48
12/11/17
09:48
Conference/Events
Spark Therapeutics to hold a pharmaceutical update conference call »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

NKE

Nike

$61.67

0.365 (0.60%)

09:47
12/11/17
12/11
09:47
12/11/17
09:47
Upgrade
Nike rating change  »

Nike upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

09:45
12/11/17
12/11
09:45
12/11/17
09:45
General news
JOLTS Job Openings to be reported at 10:00 »

October JOLTS Job…

IOTS

Adesto Technologies

$7.00

-0.45 (-6.04%)

09:44
12/11/17
12/11
09:44
12/11/17
09:44
Conference/Events
Adesto Technologies management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

09:42
12/11/17
12/11
09:42
12/11/17
09:42
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KMB

Kimberly-Clark

09:41
12/11/17
12/11
09:41
12/11/17
09:41
Technical Analysis
Technical View: Kimberly-Clark falls in early trading, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

, CELG

Celgene

$106.09

3.36 (3.27%)

09:40
12/11/17
12/11
09:40
12/11/17
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

AKS

AK Steel

CELG

Celgene

$106.09

3.36 (3.27%)

GME

GameStop

CTL

CenturyLink

X

U.S. Steel

ORCL

Oracle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

09:40
12/11/17
12/11
09:40
12/11/17
09:40
General news
Fed funds futures are flat to lower ahead of Wednesday's FOMC »

Fed funds futures are…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.